Why did APTO's EPS remain stagnant throughout 2023?

The EPS of Aptevo Therapeutics (APTO) remained stagnant throughout 2023 due to a combination of factors:

1. **Revenue Structure**: There was no available data on the income by business for APTO in 2023. This makes it difficult to analyze the revenue generation by different business segments, which could be a factor in the stagnant EPS.
2. **Financial Performance**: APTO reported a net loss of $4.34 million and a total revenue of $431,378 for the quarter ended December 31, 2023. The net loss, although slightly higher than the previous quarter, did not result in a corresponding increase in EPS. This could be due to the company's inability to leverage its revenue to cover its increasing costs or expenses.
3. **Previous Performance**: In the first quarter of 2023, APTO had a net loss of approximately $13.7 million, which translated into approximately $0.15 per share loss. This previous performance indicates that the company has been struggling with significant losses, which could be a contributing factor to the stagnant EPS.

In conclusion, the stagnant EPS of APTO throughout 2023 can be attributed to a combination of factors, including the company's revenue structure, financial performance, and previous performance.